治疗耐药性抑郁症的多次皮下注射艾斯凯坦胺:一项开放式剂量定位研究
Fernanda Palhano-Fontes1, Patricia Cavalcanti-Ribeiro2, Kaike Thiê da Costa Gonçalves3
1Brain Institute, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil; Center for Advanced Psychedelic Medicine, Natal, RN, Brazil.
Journal of affective disorders
|September 28, 2024
概括
皮下施用埃斯基坦胺在治疗耐药性抑郁症 (TRD) 中表现有前途,观察到显著的反应和缓解率. 这种可访问的方法提供了持续的抗抑郁作用,需要进一步研究.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 胺是单极治疗耐药性抑郁症 (TRD) 的领先治疗方法.
- 静脉注射 (IV) 和鼻腔内注射 (IN) 胺是常见的注射途径.
- 皮下 (SC) 乙胺提供了一个潜在的更容易获得和更具成本效益的替代方案,其血水平与静脉注射相比较,副作用较少.
研究的目的:
- 调查用于TRD的SC胺的疗效和安全性.
- 用标准化抑郁症评分表来评估抗抑郁药的效果.
主要方法:
- 一项涉及30名TRD患者的开放性临床试验.
- 进行了每周8次的SC胺治疗.
- 评估结果使用蒙哥马利-阿斯伯格抑郁症评分表和贝克抑郁症目录II (BDI-II).
主要成果:
- 根据蒙哥马利-阿斯伯格抑郁症评分表,实现了部分反应率为26.09%,反应率为52.17%,缓解率为34.78%.
- 从基线到最后一次会议,自报告的抑郁症状 (BDI-II) 显著减少.
- 通过六个月的随访评估,观察到持续的抗抑郁药物改善.
结论:
- 在TRD中,SC胺显示出有前途的反应和缓解率.
- 该疗法在六个月内表现出持续的抗抑郁作用.
- 需要进一步的研究来验证这些发现,因为样本规模小,缺乏对照组等局限性.
相关概念视频
01:30Electroconvulsive Therapy
28
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
28
01:23Antidepressant Drugs: MAOIs and Other Agents
200
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
200